ALXN Related Analyst Ratings
-
Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
-
Bank of America Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Neutral
-
Citi Upgrades Alexion Pharmaceuticals (ALXN) to Buy
-
Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)
-
ThinkEquity Starts Alexion Pharma (ALXN) at Sell
-
Piper Jaffray Resumes Coverage on Alexion (ALXN) with a Buy; Warrants Premium to Peer Group
-
Goldman Sachs Resumed Coverage on Alexion Pharmaceuticals (ALXN) at Buy
-
Brean Murray Initiates Coverage on Alexion Pharmaceutical (ALXN) with a Buy
-
Leerink Swann Starts Alexion Pharma (ALXN) at Outperform
-
Thomas Weisel Starts Alexion Pharmaceuticals (ALXN) at Overweight
-
Collins Stewart Starts Alexion (ALXN) at Buy; $95 PT
-
Piper Jaffray Resumes Alexion (ALXN) with a Buy
-
Jefferies & Co Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Buy
-
Wachovia Downgrades Alexion Pharma (ALXN) to Market Perform
-
UBS Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Buy
-
Who's The Next Biotech Target Following Celgene/Pharmion?
-
Banc of America Starts Alexion Pharmaceuticals (ALXN) at Buy
-
Credit Suisse Downgrades Alexion Pharma (ALXN) to Neutral
-
First Albany downgrades Alexion Pharma (ALXN) to Neutral
-
Credit Suisse Starts Alexion Pharmaceuticals (ALXN) at Outperform
-
Merrill Lynch Starts Alexion Pharma (ALXN) to Buy
-
Piper Jaffray Starts Alexion Pharma (ALXN) at Outperform
-
Banc of America Starts ALXN at Neutral
-
Hibernia Upped ALXN to Buy; $27 trgt
-
Hibernia Southcoast Capital Downgraded ALXN to Hold; $27 trgt
-
Morgan Stanley starts ALXN at Overweight
Back to ALXN Stock Lookup
